AC Lenvatinib plus Cisplati
Phase 2
Recruiting
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-jRCT1041220110
- Lead Sponsor
- Yamashita Tatsuya
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
clinically diagnosed as hepatocellular carcinoma; Preserved liver functional reserve and scheduled for resection; diagnosed as high-risk hepatocellular carcinoma recurrence beyond the Milan criteria; 20 years or older; ECOG Performance status <=2; preservation of major organ function; written informed consent
Exclusion Criteria
refractory ascites or pleural effusion; risky varices; double cancer; metastases to central nervous system; severe complication; pregnant or lactating women, or women of childbearing potential; mental disorder; patients who investigator regards as inappropriate for candidate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to recurrence beyond the Milan criteria
- Secondary Outcome Measures
Name Time Method progression-free survival, overall survival, objective response rate, tumor control rate, adverse events, liver functional reserve, subsequent therapies